Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  liposomal cytarabine-daunorubicin CPX-351
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-7 of 7 for your search:
Start Over
CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 60 and over
Sponsor: NCI, Other
Protocol IDs: HEM0036, NCI-2013-01982, 4593, P30CA124435, 28524, NCT02019069
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLTR0310-206, NCT02238925
Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLTR0314-208, NCT02269579
Phase II CPX-351 in Acute Myeloid Leukemia (AML)
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 2014-0548, NCI-2014-02529, NCT02286726
Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 30
Sponsor: Other
Protocol IDs: CPX-MA-1201, 2013-4305, NCT01943682
Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2642.00, NCI-2013-00481, 2642, P30CA015704, NCT01804101
Start Over